ARTICLE | Clinical News
Arikace: Phase II started
May 28, 2012 7:00 AM UTC
Insmed began the double-blind, placebo-controlled, U.S. Phase II TARGET-NTM trial to evaluate once-daily 560 mg Arikace administered with the eFlow Nebulizer System from Pari GmbH (Starnberg, Germany...